WHO ICTRP trial
Clinical study on efficacy and safety of VA combined with Gilteritinib for…
ChiCTR2500098586 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500098586 |
|---|---|
| Public title | Clinical study on efficacy and safety of VA combined with Gilteritinib for treatment of de novo AML with NPM1mut/FLT3/ITDmut/DNMT3Amut |
| Scientific title | Clinical study on efficacy and safety of VA combined with Gilteritinib for treatment of de novo AML with NPM1mut/FLT3/ITDmut/DNMT3Amut |
| Primary sponsor | The first affiliated hostipal of nanchang university |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | De novo AML with NPM1, FLT3/ITD and DNMT3A triple mutations |
| Interventions | GVA group:VA combined with Gilteritinib regimen |
| Registration date | Mar 11, 2025 |
| Target size | GVA group:32 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: